John David Scandling, MD
Nephrology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Scandling’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G66051 · Current
Licensed to practise in California · since 1989 · expires 2028-09-30 · Virginia Commonwealth University, Medical College of Virginia.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$3,900 in 2022
Medicaid paid $3,900 for 94 billed services this clinician did in 2022, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 43 | $2,071 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 51 | $1,829 |
| 2022 | 94 | 2 | 14 | $3,900 |
Money from drug and device companies
$168 in 2022
| 2022 | 1 | 1 | None | $168 |
| 2019 | 2 | 4 | $2,600 | $2,766 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Horizon Therapeutics plc | Krystexxa | $168 | 1 payment
|
See the published payment
| Horizon Therapeutics plc | Meals · 2022-06-08 | Krystexxa | $168 |
See earlier years (2019)
2019: $2,766
| Mallinckrodt Enterprises | Acthar | $2,166 | 3 payments
|
| Horizon Therapeutics plc | None | $600 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study To Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 Kg M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease · 2025 | This clinician | $5,175 |
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study To Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 Kg M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease · 2025 | Their institution | $1,350 |
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study To Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 Kg M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease · 2024 | Their institution | $675 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1174665020
- Licence
- CA G66051California G66051: Current · expires 2028-09-30
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G660510
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-13
- NPI last updated
- 2024-04-23
- NPI record certified
- 2024-04-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 750 Welch Road, Palo Alto, CA, 94304 · 1500 E 2nd St Ste 300, Reno, NV, 89502